Key result
Thromboprophylaxis was used in 23.3% of surgical procedures in patients with inherited platelet disorders and was associated with zero venous thromboembolic events, whereas two events occurred in patients without prophylaxis.
Why the study?
The incidence of VTE and the current use and safety of thromboprophylaxis, particularly low-molecular-weight-heparin, in patients with inherited platelet disorders undergoing surgery are unknown.
Does thromboprophylaxis prevent venous thromboembolism in patients with inherited platelet disorders undergoing surgery?
Population
155 patients with well-defined forms of IPD undergoing 210 surgical procedures
Comparison
Thromboprophylaxis vs no thromboprophylaxis
Design
Multicenter observational study
Authors
Loading...
Thromboprophylaxis may be considered in surgical patients with inherited platelet disorders; hypothesis-generating and requires prospective trials before practice change.
Observational (n=155)
Yes
Does thromboprophylaxis prevent venous thromboembolism in patients with inherited platelet disorders undergoing surgery?
Absolute Event Rate: 0% vs 1.2%
In patients with inherited platelet disorders, VTE incidence is low but predicted by the Caprini score, and thromboprophylaxis (mechanical or LMWH) appears safe and effective without increasing bleeding risk.
Paciullo et al. (2019) conducted an observational in Inherited platelet disorders (n=155). Thromboprophylaxis (mechanical or pharmacologic) vs. No thromboprophylaxis was evaluated on Symptomatic venous thromboembolism (VTE) within one month after surgery. Thromboprophylaxis was used in 23.3% of surgical procedures in patients with inherited platelet disorders and was associated with zero venous thromboembolic events, whereas two events occurred in patients without prophylaxis.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: